TB4 vs TB-500: Why the Full Peptide Beats the Fragment

The two names get used interchangeably — but they are not the same molecule, and the difference decides whether the research even applies to what’s in your vial.

Abstract: TB4 vs TB-500 is the most common point of confusion in healing peptides: TB-500 is only the 7-amino-acid actin-binding fragment (LKKTETQ) of the full 43-amino-acid peptide thymosin β4 (TB4). Because almost every tissue-repair study was run on full-length TB4 — not the fragment — the evidence does not transfer one-to-one, which is why understanding the distinction matters before you compare, source, or stack either one.

If you have shopped for healing peptides, you have seen “TB4” and “TB-500” used as if they were synonyms. They are not. TB4 vs TB-500 is not a brand argument — it is a structural one, and it changes how much of the published research actually applies to the product you are holding. Get this wrong and you can buy a fragment while reading the data for the whole peptide.

This guide separates the two cleanly: what each molecule is, where the evidence sits (human vs animal), how they differ in dosing and forms, the cancer-risk nuance most vendor pages skip, and how to verify which one you actually received. Everything here is framed for research and educational use only — not medical advice.

TB4 vs TB-500: the one-sentence answer

TB4 (thymosin β4) is the complete 43-amino-acid peptide. TB-500 is only a 7-amino-acid fragment of it (residues 17–23, the sequence LKKTETQ). The fragment carries TB4’s central actin-binding site, so it reproduces some of TB4’s activity — but it is missing every other functional region of the parent molecule. The practical consequence: nearly all the tissue-repair evidence was generated with full-length TB4, and those findings do not translate cleanly to the fragment.

That is the inversion most search results get wrong. Several popular vendor pages claim TB-500 “focuses on muscle repair” while TB4 handles skin and cell migration — but the bulk of the musculoskeletal, cardiac, and wound data was run on TB4 itself. TB-500 alone has surprisingly little direct evidence that it even works at the level people assume.

What TB4 actually is

Thymosin β4 is a beta-thymosin — a family of small proteins found in essentially every nucleated cell, where TB4 is both the most abundant and the most studied member. It is structurally and functionally distinct from the alpha-thymosins like thymosin alpha-1, which are immune-signalling peptides rather than structural-repair ones. Confusing “thymosin” as one thing is a second, separate source of error.

TB4 is best understood as a multi-segment molecule, where different stretches of the 43-amino-acid chain do different jobs:

• Residues 17–23 (the part TB-500 copies): binds G-actin, stabilising the actin building blocks cells use to crawl. This drives cell migration and angiogenesis — endothelial cells migrating to line new blood vessels. This is the core repair engine, and the only piece TB-500 reproduces. The actin-sequestering role and its repurposing for tissue repair were characterised by Goldstein and colleagues, who described TB4 as an actin-sequestering protein that “moonlights” to repair injured tissue.
• The first 4 residues: anti-inflammatory and anti-scar activity.
• The first 15 residues: pro-survival / anti-apoptotic signalling — keeping stressed cells alive long enough to repair.
• Additional regions: antimicrobial activity plus gene- and signalling-pathway activation.

TB-500 contains the first item on that list and none of the rest. So the fragment can plausibly help with the actin-migration arm of healing, but the anti-scar, pro-survival, and antimicrobial contributions of the parent peptide are simply absent.

The evidence: what was studied (and on which molecule)

Here is the part that decides the comparison. Provenance matters, so each claim below is labelled — human clinical, animal, or educational-synthesis.

Human data (all on TB4, not the fragment):

• Skin / chronic wounds — strongest human signal. A phase-2 trial (~73 patients) reported accelerated chronic-wound healing by roughly a month, using a topical 0.03% gel daily for up to three months. (Provenance: educational synthesis of clinical data.)
• Eye / cornea. A phase-3 trial (~18 patients) reported corneal healing of about 60% vs 13% on placebo and improvement in moderate-to-severe dry eye, using a 0.1% solution dosed 4–6× daily for up to 28 days. (Educational synthesis.)
• Heart. A small pilot (~10 patients) found TB4-pretreated stem cells improved heart function by roughly 50% and walking distance by ~14% versus untreated stem cells. (Educational synthesis; hypothesis-generating, not a standalone TB4 efficacy trial.)

Animal data (also TB4):

• Cardiac. Bock-Marquette and colleagues showed in Nature (2004) that thymosin β4 forms a complex with PINCH and integrin-linked kinase (ILK), activating Akt, and after coronary ligation in mice enhanced cardiomyocyte survival and cardiac function — the foundational repair mechanism. (Animal; peer-reviewed.)
• Musculoskeletal. Mouse fracture models showed stiffer, stronger bone (~+25% stiffness, ~+41% force to refracture) and 2–3× faster, dose-dependent muscle repair. (Animal.)
• Hair. Philp et al. (2004) reported TB4 increased hair growth by activating hair-follicle stem cells in rodents. (Animal.)
• Brain. Mouse stroke and TBI models showed better functional recovery via vessel remodelling, neuron growth, and cell protection. (Animal.)

TB-500 (the fragment), studied alone: comparatively little. The fragment is assumed to inherit the actin-migration benefit, but the human and most animal evidence above was generated with the full peptide. That asymmetry is the entire case for preferring TB4.

This is why our TB-500 healing research overview and the deeper data here both lean on TB4’s literature: the evidence base is TB4’s, borrowed by the fragment.

TB4 vs TB-500 at a glance

	TB4 (thymosin β4)	TB-500 (fragment)
Structure	Full 43-amino-acid peptide	7-amino-acid fragment (aa 17–23, LKKTETQ)
Functional regions	Actin-binding + anti-scar + anti-apoptotic + antimicrobial + signalling	Actin-binding only
Evidence base	Human trials (skin, eye, cardiac pilot) + broad animal data	Sparse direct evidence; inherits TB4 claims by assumption
Half-life	Short (~1.5 h) → typically dosed daily	Longer (metabolites ~72 h) → 2–3×/week feasible
Forms	Topical (skin/eye), SubQ (MSK/cardiac/neuro). Not orally bioavailable	Same constraint — no oral
Best framing	The better-studied, more complete molecule	A convenience-dosed partial; verify you’re not getting it mislabelled as TB4

Dosing, forms, and cycling (research-reported)

These are the parameters reported in research and educational synthesis — recorded here for understanding, not as a personal directive.

• Forms. Topical for skin and eye; subcutaneous for musculoskeletal, cardiac, or neuro contexts. Neither molecule is orally bioavailable — unlike acid-resistant BPC-157, TB4 has no oral studies, so oral “TB-500” products lack a rationale.
• Dose (SubQ, hypothetical). Anchored to TB4’s human IV-safety data (~5 mcg/kg), a subcutaneous equivalent works out near ~7.14 mcg/kg → roughly ~500 mcg/day for a 70 kg adult, up to ~1 mg if needed.
• Frequency. This is where the half-life difference bites: TB4 is dosed daily (~1.5 h half-life) for steadier levels, while TB-500’s longer-lived metabolites (~72 h) make a 2–3×/week schedule workable. The fragment’s main practical advantage is dosing convenience, not superior healing.
• Cycling. Research framing uses roughly 4–6 weeks on / ≥6 weeks off — shorter than a typical BPC-157 cycle, reflecting the more cautious cancer-risk framing below. Targeted, time-limited use; no evidence supports indefinite or preventive dosing.

The cancer-risk nuance vendor pages skip

The same mechanisms that make TB4 a repair peptide — angiogenesis, cell migration / epithelial-mesenchymal transition, anti-apoptosis, and anti-ferroptosis — are also mechanisms a pre-existing cancer could exploit to grow, invade, or survive. Educational synthesis rates full-length TB4 as carrying a slightly higher theoretical cancer-promotion concern than BPC-157, precisely because it is the more complete, more potent molecule. Human safety data is reassuring for short courses (phase-1 IV up to 1,260 mg/day for 14 days; topical for 3 months) with no toxicities observed — but there is no long-term post-course human data.

The research-cautious reading: avoid with any personal or family cancer history or precancerous lesion, treat use as short-term and targeted only, and never as indefinite “preventive” maintenance. See our peptide side effects and safety guide for the broader risk framing.

How to verify which one you’re actually getting

Because TB-500 is cheaper to synthesise than the full 43-amino-acid peptide, mislabelling runs in one direction: a fragment sold as “TB4.” Compounding pharmacies cannot legally produce TB4 at present, so most research-grade supply is unregulated. If a product is being used for research at all, the COA bar is non-negotiable:

• HPLC + mass-spec identity and purity — mass spec is the only way to confirm you have the full 43-amino-acid TB4 and not the 7-amino-acid fragment relabelled. A purity percentage alone won’t tell you which molecule it is.
• USP <85> endotoxin and USP <71> sterility for any injectable.
• Match the COA’s stated identity and mass to full-length TB4 specifically.

A regulated compounding pharmacy is far safer than a research-use-only vendor; verification matters most precisely because the cheaper molecule is the easy substitution. Whatever the source, treat the COA — not the label on a research-grade TB-500 vial — as the real identity check.

Should you stack them — and with what?

For musculoskeletal repair, the research-reported hierarchy actually favours BPC-157 first (more and stronger animal data, and a lower cancer-risk framing), adding TB4 only if healing plateaus — and starting both together for acute major injuries, post-surgery, stroke, or major TBI, where TB4 acts as an early repair signal. The two are mechanistically synergistic: TB4 works through actin and cell structure, BPC-157 through nitric-oxide and VEGF-driven angiogenesis. That logic is the basis of the popular BPC-157 + TB-500 “Wolverine” stack, offered as a pre-mixed BPC-157 + TB-500 blend — and a reason the distinction in this article matters even inside a blend: you want the stack built on full TB4, not the fragment.

FAQ

Is TB4 the same as TB-500? No. TB4 (thymosin β4) is the complete 43-amino-acid peptide; TB-500 is a 7-amino-acid fragment of it (residues 17–23). They share one functional region — the actin-binding site — but TB-500 lacks TB4’s anti-scar, pro-survival, antimicrobial, and signalling segments.

Which is better, TB4 or TB-500? On the evidence, full-length TB4 is the better-supported choice: almost all the human and animal tissue-repair data was generated with TB4, not the fragment. TB-500’s main edge is dosing convenience (less frequent injections), not stronger healing.

Why do people say TB-500 when they mean TB4? Historical shorthand. “TB-500” became a generic market name for “thymosin β4 product,” so the fragment’s name got attached to the whole peptide’s reputation and data. The names blurred; the molecules did not.

Can you take TB4 or TB-500 orally? There is no evidence for it. Unlike acid-resistant BPC-157, TB4 is not orally bioavailable and has no oral studies, so oral “TB-500” products lack a research basis. Studied routes are topical (skin/eye) and subcutaneous.

Is TB4 safe? Short-course human safety data is reassuring (no toxicities at high IV doses over two weeks), but there is no long-term post-course data, and its repair mechanisms carry a theoretical cancer-promotion concern — rated slightly higher than BPC-157. It is contraindicated in research framing for anyone with a cancer history or precancerous lesion.

References

1. Bock-Marquette, I., et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. doi:10.1038/nature03000. PMID 15565145.
2. Philp, D., et al. (2004). Thymosin beta 4 increases hair growth by activation of hair follicle stem cells. FASEB Journal, 18(2), 385–387.
3. Goldstein, A. L., Hannappel, E., & Kleinman, H. K. (2005). Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9), 421–429.
4. Educational study-synthesis (licensed-MD secondary source), summarising TB4 human trials in chronic skin wounds (phase-2, ~73 patients), corneal/dry-eye healing (phase-3, ~18 patients), and a cardiac stem-cell pilot (~10 patients). Provenance: educational/anecdote, not primary literature.

---

Research and educational use only. This article summarises published and educational sources for informational purposes and is not medical advice. Nothing here is a recommendation to diagnose, treat, cure, or prevent any condition, or to dose any compound. Peptides discussed are not FDA-approved for these uses. Consult a qualified clinician before acting on any health information. Evidence is graded honestly: where data is animal-only or from educational synthesis rather than human clinical trials, it is labelled as such.